Scotiabank Maintains Outperform on Vertex Pharmaceuticals (VRTX) Feb 13, 2026
VRTX analyst rating: Scotiabank maintained an Outperform on Vertex Pharmaceuticals Incorporated (VRTX) on February 13, 2026, and raised its price target to $558. The same day Morgan Stanley kept an Overweight and nudged its target to $570. Both firms left ratings intact, signaling ongoing confidence in Vertex’s franchise and pipeline. These moves update investor expectations about upside and valuation on the same trading day.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
